Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion
NASDAQ:OCS

Oculis Q3 2026 Earnings Date & Estimates

Oculis logo
$7.96 +0.06 (+0.76%)
Closing price 04:00 PM Eastern
Extended Trading
$8.10 +0.14 (+1.76%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oculis is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. The conference call is scheduled for 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Oculis in Q3 2026

Oculis is expected to post earnings of -$0.49 per share on revenue of $247 thousand. In the same quarter a year earlier Oculis reported -$0.40 per share on revenue of $305 thousand. Oculis last reported on August 6, 2026, posting -$0.20 per share and beating the -$0.48 consensus estimate. Oculis has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.49
Expected Revenue
$247 thousand
Prior-Year EPS
-$0.40
Prior-Year Revenue
$305 thousand
Expected Revenue Growth
-19.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.20 (Beat by +$0.28)
Last Quarter Revenue
$383.29 thousand
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Oculis Q3 2026 Earnings FAQ

Oculis (NASDAQ:OCS) is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Oculis' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Oculis to post earnings of -$0.49 per share for Q3 2026.

The consensus revenue estimate for Oculis is $247 thousand for Q3 2026.

Oculis Earnings Headlines

Oculis Reports New Phase 2 Privosegtor Biomarker Findings In Optic Neuritis
October 22, 2026  |  rttnews.comhttps://www.rttnews.com/3701567/oculis-reports-new-phase-2-privosegtor-biomarker-findings-in-optic-neuritis.aspx
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
October 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/oculis-reports-new-phase-2-acuity-biomarker-data-further-supporting-privosegtor-s-neuroprotective-potential-in-optic-neuritis-1036653216
Why Some AI Stocks Already Surged Over 300 Percent
Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run, and Vertiv before a 1900 percent run. Now he's tracking a radical light-speed technology that could make AI 100 times faster and 100 times more energy efficient. Stocks tied to it have already climbed 133 percent, 217 percent, and 320 percent.tc pixel
October 26 at 1:00 AM  |  Brownstone Research (Ad)
Oculis Reports Privosegtor Reduced NfL and GFAP Biomarkers vs. Placebo in Phase 2 Optic Neuritis Trial
October 22, 2026  |  quiverquant.comQ
Oculis Reports Reduced NfL and GFAP Increases with Privosegtor in Phase 2 ACUITY Optic Neuritis Trial
October 22, 2026  |  quiverquant.comQ
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis
October 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/22/3386036/0/en/oculis-reports-new-phase-2-acuity-biomarker-data-further-supporting-privosegtor-s-neuroprotective-potential-in-optic-neuritis.html
See More Oculis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oculis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oculis and other key companies, straight to your email.

About Oculis

Oculis (NASDAQ:OCS) is a global biopharmaceutical company focused on developing innovative treatments for eye diseases. The company’s research is centered on therapies that can be administered directly to the eye, including topical ophthalmic formulations and other approaches designed to improve drug delivery, efficacy, and patient convenience.

Oculis has developed a pipeline addressing ophthalmic conditions such as retinal diseases, diabetic macular edema, dry eye disease, and other disorders that can impair vision. Its investigational programs have included OCS-01, a topical dexamethasone formulation being studied for inflammatory eye conditions including diabetic macular edema, and licaminlimab, an anti-tumor necrosis factor therapy investigated for ocular surface disease. The company has also pursued treatments intended to protect or preserve retinal and optic nerve function.

Founded in 2019, Oculis is headquartered in Zug, Switzerland, and serves international markets through its global research and development activities. The company became publicly listed on the Nasdaq under the symbol OCS in 2023. Oculis is led by Chief Executive Officer Riad Sherif, who has experience in the pharmaceutical and ophthalmology sectors.

View Oculis Profile
Earnings Tools